跳至主要内容
临床试验/NCT00649831
NCT00649831已完成3 期

Azithromycin (Zithromax®) 5 Days Versus Amoxicillin-Clavulanic Acid (Augmentin®): Multicentre, Randomised, Open-Label Study To Compare The Clinical Efficacy And Safety Of Azithromycin With Those Of Amoxicillin-Clavulanic Acid In Patients Presenting With An Exacerbation Of Chronic Bronchitis

Pfizer1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2002年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Pfizer
入组人数
250
试验地点
1
主要终点
To assess clinical efficacy (clinical recovery or clinical failure)

研究概览

简要总结

This study compared the clinical efficacy and safety of azithromycin with that of amoxicillin-clavulanic acid, in patients between the ages of 35 and 75 years, presenting with an exacerbation of chronic bronchitis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
36 Years 至 74 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion Criteria:
  • Outpatients presenting with an exacerbation of chronic bronchitis including: chronic bronchitis with obstructive respiratory disorders documented by a forced expiratory volume of below 80% and higher than 35% of the theoretical value, within the previous 12 months; and thought to be of infectious origin

排除标准

  • Exclusion Criteria:
  • Patient not presenting with the associated signs of an exacerbation
  • Patient presenting with clinical signs suggestive of pneumonopathy at inclusion
  • Patient requiring hospitalisation in intensive care

研究组 & 干预措施

Group 2

Active Comparator

干预措施: Amoxicillin/clavulinic acid (Drug)

Group 1

Active Comparator

干预措施: Azithromycin (Drug)

结局指标

主要结局

To assess clinical efficacy (clinical recovery or clinical failure)

时间窗: Day 30

次要结局

  • Bacteriological monitoring (a descriptive analysis of streptococci in the bacterial flora and their sensitivity to antibiotics at the different collections of sputum)(continuous)
  • Number of exacerbations(Day 30 to Day 90)

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验